Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02886702 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis
A Phase 3 study, sponsored by Fougera Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 855
- Enrollment target
NCT02886702: Completed Phase 3 study, sponsored by Fougera Pharmaceuticals.
NCT02886702 is a Phase 3 study that has completed, run by Fougera Pharmaceuticals. The registered enrollment target is 855 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02886702, a Phase 3 study, has completed, sponsored by Fougera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 855 participants
- Enrollment target
Study Summary
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis
Primary Outcome
Proportion of subjects with treatment success (defined as none, minimal or mild disease, a score of 0, 1 or 2 within the treatment area) on the "Investigator's Global Assessment of Disease Severity" (IGA) at the Week 12 visit (Day 85 ± 4 days, End of Study).
Interventions
- DRUG Placebo
- DRUG Tazarotene Cream 0.05%
- DRUG TAZORAC® (tazarotene) Cream 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 855 participants |
| Start Date | 2016-09-19 |
| Est. Completion | 2017-08-02 |
| Phase | Phase 3 |
What the finished NCT02886702 record still lists
NCT02886702 is an interventional study that assigns participants to a tested intervention. The registered 855 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02886702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02886702 about?
NCT02886702 is a clinical study titled "A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis". A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis
What is the current status of trial NCT02886702?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 855 participants. The study started on 2016-09-19. Estimated completion is 2017-08-02.
What interventions are being tested in trial NCT02886702?
The interventions under investigation include: Placebo (DRUG), Tazarotene Cream 0.05% (DRUG), TAZORAC® (tazarotene) Cream 0.05% (DRUG).
Who is sponsoring clinical trial NCT02886702?
This trial is sponsored by Fougera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02886702's enrollment target sits among peer trials
855 384th of 2000 higher than 1,617 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
- NCT06231485 · 856 participants · NA
Socialization To Enrich Participation & Support Sexuality for Young People With I/DD
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI